Gilead's HIV Franchise and Oncology Pipeline Could Tell Two Different Stories This Quarter

Gilead Sciences (GILD) reports first-quarter 2026 earnings tomorrow, May 7, after the market close, with analysts expecting $1.89 per share on the strength of its HIV franchise and emerging oncology portfolio. The report arrives as the biopharmaceutical giant navigates policy-driven pricing headwinds while attempting to prove its diversified pipeline can offset declining COVID-related revenue and competitive pressures in cell therapy. With the stock trading at $136.30 and Wall Street's consensus price target implying 17% upside, investors will scrutinize whether management's conservative 2026 guidance—calling for 4–5% base business growth—leaves room for positive surprises or signals a prolonged period of modest expansion.

Part 1: Earnings Preview

Gilead Sciences is a leading biopharmaceutical company focused on developing and commercializing innovative medicines in HIV, viral hepatitis, oncology, and inflammation, with flagship products including Biktarvy for HIV treatment and Trodelvy for cancer. The company's diversified portfolio and late-stage pipeline position it as a key player in specialty pharmaceuticals, though it faces ongoing challenges from policy changes and competitive dynamics.

Gilead reports first-quarter 2026 results on May 7 after the market close, with the consensus estimate calling for $1.89 per share. The company most recently reported $1.86 per share for the fourth quarter of 2025, beating estimates by $0.03. Compared to the same quarter last year, when Gilead earned $1.81 per share, the current estimate implies 4.4% year-over-year growth—a modest acceleration that reflects both the company's commercial execution and the drag from known policy headwinds.

Three key themes define this earnings story:

HIV Franchise Resilience and YES2GO Momentum: Gilead's HIV business remains the revenue engine, with Biktarvy commanding over 52% U.S. market share and full-year 2025 sales of $14.3 billion. The critical question is whether the company can sustain its guided 6% HIV growth despite an estimated 2% drag from Medicare Part D redesign and the December drug-pricing agreement. Management's projection of roughly $800 million in YES2GO revenue for 2026—up from $150 million in 2025—suggests the HIV prevention franchise could provide meaningful upside if adoption continues to exceed expectations. Investors will parse prescription trends and payer coverage updates to assess whether the prevention opportunity can offset treatment pricing pressures.

Pipeline Catalysts and Oncology Expansion: Gilead has positioned 2026 as "catalyst-rich," with multiple Phase III readouts and up to four potential commercial launches including Trodelvy in first-line triple-negative breast cancer, Viclen (bictegravir+lenacapavir), Anidocel, and bruleviratide. The company's oncology ambitions hinge on Trodelvy's label expansion—full-year 2025 sales reached $1.4 billion, up 6%—and the highly differentiated Anidocel data showing 96% overall response rates in multiple myeloma. Any updates on regulatory timelines, competitive positioning, or early launch metrics will signal whether Gilead can credibly diversify beyond HIV and offset the anticipated 10% decline in Kite cell therapy revenue.

Navigating Policy Headwinds and Margin Discipline: Management has been transparent about near-term pressures: the Part D/Medicaid/ACA changes are expected to shave roughly 2 percentage points off HIV growth, Vecluri (COVID) revenue is projected to fall to approximately $600 million in 2026 from $900 million in 2025, and Kite faces competitive erosion. The company's ability to maintain its guided 87% product gross margin and deliver non-GAAP EPS of $8.45–$8.85 for the full year depends on disciplined cost management and avoiding further pricing concessions. Investors will scrutinize whether Q1 results support the conservative guidance or reveal additional headwinds that could pressure the full-year outlook.

Analyst commentary ahead of the release emphasizes cautious optimism. Wall Street acknowledges Gilead's strong commercial execution—particularly the Biktarvy franchise and YES2GO launch—but remains focused on whether the company can offset known headwinds with pipeline progress. The consensus view is that Gilead's valuation reflects the policy risks, leaving room for upside if the company demonstrates operational leverage or accelerates its oncology transformation. Analysts are watching for any commentary on M&A strategy, given management's stated discipline on acquisitions, and whether the company will maintain its commitment to returning at least 50% of free cash flow to shareholders.

Part 2: Historical Earnings Performance

Gilead has demonstrated consistent ability to meet or exceed earnings expectations over the past four quarters, with three beats and one narrow miss. In Q1 2025, the company reported $1.81 per share against an estimate of $1.82, missing by just 0.55%—a negligible shortfall. The subsequent three quarters showed progressively stronger performance: Q2 2025 delivered $2.01 versus $1.95 expected (+3.08%), Q3 2025 posted $2.47 against $2.15 (+14.88%), and Q4 2025 came in at $1.86 versus $1.83 (+1.64%).

The Q3 2025 result stands out as an outlier, with the 14.88% beat representing the largest surprise in the recent history. This exceptional performance likely reflected stronger-than-expected HIV franchise momentum and Trodelvy uptake, as well as favorable timing on certain revenue items. The more typical pattern shows beats in the 1–3% range, suggesting Gilead's guidance tends to be conservative but achievable, with occasional upside when commercial execution or pipeline milestones exceed expectations.

The trend is modestly positive, with the company beating estimates in three of the past four quarters and the single miss being immaterial. This pattern suggests management has recalibrated guidance to reflect the policy headwinds and competitive pressures, setting a bar that the business can consistently clear. For the upcoming Q1 2026 report, the 4.4% year-over-year growth implied by the $1.89 estimate appears achievable given the company's track record, though investors should watch for whether Gilead can deliver another modest beat or if the policy drags prove more severe than anticipated.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Gilead Sciences typically reports earnings after the market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Gilead's post-earnings price behavior shows significant volatility, with an average absolute Day +1 move of 4.38% and a range of 5.75%, indicating the stock frequently experiences sharp reactions once results are digested. The Day 0 moves are more muted, averaging 1.30%, which is consistent with after-hours reporting where the market has limited information before the close.

The direction of moves has been predominantly positive in recent quarters, with five of the past eight Day +1 sessions closing higher. The largest single-day gain came on August 7, 2025, when the stock surged 8.28% following a Q2 beat, and February 10, 2026, saw a 5.82% rally after the Q4 2025 report. Conversely, the most significant decline occurred on April 24, 2025, with a 2.81% drop despite a narrow earnings miss, suggesting the market was disappointed by guidance or commentary rather than the headline number.

The pattern suggests investors should prepare for a move in the 4–6% range following tomorrow's report, with the direction likely determined by whether Gilead reaffirms or adjusts its full-year guidance and provides confidence on the HIV franchise's ability to offset policy headwinds. The historical data indicates that beats accompanied by constructive commentary tend to generate outsized gains, while even modest misses or cautious guidance can trigger sharp selloffs.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 3.97% for the May 8 expiration, which is slightly below the stock's average historical Day +1 move of 4.38% but well within the typical range. This suggests options traders are anticipating a meaningful reaction but not an outsized surprise, consistent with Gilead's recent pattern of modest beats and relatively stable guidance. The implied move of $5.41 in either direction sets the range at $130.89 to $141.71, providing a clear framework for evaluating whether the post-earnings move is in line with or exceeds market expectations.

Part 3: What Analysts Are Saying

Analysts maintain a Strong Buy consensus on Gilead Sciences, with the average recommendation at 4.44 out of 5.00. The current breakdown shows 22 Strong Buy ratings, 2 Moderate Buys, and 8 Holds, with no sell ratings among the 32 analysts covering the stock. This overwhelmingly bullish stance reflects confidence in the company's HIV franchise durability, pipeline potential, and ability to navigate near-term policy headwinds.

The average price target of $159.76 implies 17.2% upside from the current price of $136.30, with the range spanning from a low of $123.00 to a high of $180.00. The wide spread in targets—$57 from low to high—suggests differing views on the pace of Gilead's oncology transformation and the severity of pricing pressures, but even the most conservative target sits near current levels, indicating limited downside risk in the analyst community's view.

Sentiment has remained unchanged over the past month, with the rating distribution and average recommendation holding steady at 4.44. This stability suggests analysts are comfortable with their current views heading into earnings, having already incorporated the known policy headwinds and conservative 2026 guidance into their models. The lack of recent downgrades or upgrades indicates the Street is waiting for the Q1 report and management commentary to provide new information before adjusting estimates or price targets.

The consensus view positions Gilead as a high-conviction buy with moderate upside, reflecting a belief that the stock's current valuation adequately discounts near-term challenges while undervaluing the long-term pipeline opportunity. The absence of sell ratings and the concentration of Strong Buy recommendations underscore analysts' confidence that the company's diversified portfolio and disciplined capital allocation will drive sustained shareholder returns, even as the HIV business matures and oncology investments ramp.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a Buy signal at 24%, down from 40% a month ago but up from 8% last week, indicating recent short-term improvement after a period of weakening momentum. This fluctuation suggests the stock has experienced volatility in the lead-up to earnings, with the current reading reflecting a tentative bullish tilt that remains well below the strong conviction levels seen earlier in the year.

Timeframe Analysis:

• Short-term (Hold): Neutral signal suggests near-term momentum is balanced, with neither bulls nor bears in clear control heading into the earnings release
• Medium-term (50% Buy): Moderate buy signal indicates the intermediate trend remains constructive, though not decisively bullish
• Long-term (50% Buy): Moderate buy signal reflects a positive longer-term outlook, consistent with the stock's position above its 200-day moving average

Trend Characteristics: The trend is characterized as Weak and Weakening, suggesting diminishing momentum and a lack of strong directional conviction as the stock approaches earnings. This environment implies heightened sensitivity to the report's outcome, with the potential for sharp moves in either direction depending on whether results and guidance exceed or disappoint expectations.

Gilead is trading above its 5-day ($132.99), 10-day ($131.49), and 200-day ($127.18) moving averages, indicating short-term strength and long-term uptrend support. However, the stock sits below its 50-day ($139.40) and 100-day ($136.56) moving averages, suggesting it has pulled back from recent highs and is testing intermediate support. The current price of $136.30 is essentially at the 100-day average, making this a critical technical juncture.

The 50-day moving average at $139.40 represents near-term resistance, while the 200-day at $127.18 provides a key support level roughly 7% below current prices. The stock's position between these two averages, combined with the weakening trend characteristics, suggests a neutral-to-cautious technical setup heading into earnings. A strong beat and constructive guidance could propel the stock back above the 50-day and reignite bullish momentum, while a disappointment risks a test of the 200-day support. The overall technical picture is neither strongly supportive nor decisively bearish, leaving the fundamental outcome of tomorrow's report as the primary driver of near-term direction.